CJC-1295 with DAC¶
CJC-1295 with DAC (Drug Affinity Complex, CAS 863288-34-0) is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH 1–29) with a molecular weight of approximately 3,649 Da. The key structural innovation is the covalent attachment of a maleimidopropionic acid-functionalized lysine residue at position 21, which enables irreversible binding to serum albumin cysteine-34 via a Michael addition reaction. This DAC conjugation extends the circulating half-life from minutes to approximately 6–8 days, making CJC-1295 with DAC a research tool for sustained, continuous GHRH receptor activation.
Technical Specifications¶
| Property | Value |
|---|---|
| CAS Number | 863288-34-0 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | ~3,649 Da |
| Purity | ≥99% (HPLC-verified) |
| Appearance | Lyophilized white powder |
| Solubility | Soluble in aqueous buffers |
| Storage | -20°C (lyophilized), 2–8°C (reconstituted) |
Mechanism of Action¶
CJC-1295 with DAC binds to the GHRH receptor on pituitary somatotrophs, activating Gαs/adenylyl cyclase to increase intracellular cAMP and stimulate pulsatile growth hormone secretion. The DAC maleimide moiety reacts selectively with the free thiol group of cysteine-34 on human serum albumin in the circulation, forming a stable covalent thioether bond. This albumin conjugation dramatically extends the peptide's half-life by preventing renal clearance, reducing proteolytic degradation, and creating a circulating depot. Unlike endogenous GHRH — which is rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) at the Ala²-Asp³ bond — CJC-1295 incorporates D-Ala² and other modifications that confer substantial resistance to proteolytic inactivation. The extended-duration GH elevation maintains sustained IGF-1 levels without the need for frequent research dosing.
Research Applications¶
- Primary: Growth hormone axis pharmacology — sustained GHRH receptor activation, pulsatile vs. continuous GH secretory patterns
- Secondary: IGF-1 regulation studies, body composition and protein synthesis research, GH deficiency models
- Model Systems: In vitro (rat pituitary cell assays, GHRH-R binding studies), in vivo (swine and rodent GH secretion models)
Quality Control & Analytical Methods¶
- HPLC: ≥99% purity verification at 214/220 nm (C18 reversed-phase column)
- Mass Spectrometry: ESI-MS for molecular weight confirmation (~3,649 ±1.0 Da)
- Peptide Content: Amino acid analysis (AAA) for net peptide content determination
- Endotoxin: <1 EU/mg (LAL assay)
- TFA Content: <1% (ion chromatography)
Stability & Storage¶
| Condition | Stability |
|---|---|
| -20°C (lyophilized) | 24 months |
| 4°C (lyophilized) | 6 months |
| 25°C (lyophilized) | 1 month |
| Reconstituted (4°C) | 7 days |
| Reconstituted (-20°C) | 30 days |
Key Research References¶
- Teichman et al. (2006) — CJC-1295, a long-acting GHRH analog, demonstrates dose-dependent GH and IGF-1 increases. J Clin Endocrinol Metab. PMID: 16434580
- Sackmann-Sala et al. (2009) — CJC-1295 prolongs the GH half-life and increases IGF-I concentrations. Growth Horm IGF Res. PMID: 19428564
- Jetté et al. (2005) — Albumin-conjugated GHRH analog CJC-1295 for GH stimulation. Endocrinology. PMID: 15790735
Source & Purchase¶
For researchers requiring research-grade CJC 1295 DAC with full analytical documentation including HPLC, LC-MS, and Certificate of Analysis, visit the HK Peptides product page for specifications, bulk pricing, and ordering.
Related Molecules¶
- CJC-1295 (no DAC) — Short-acting GHRH analog
- Sermorelin — GHRH 1-29 analog
- Tesamorelin — Full-length GHRH analog
- All Product Specifications
FAQ¶
Q: What purity level is standard for CJC-1295 with DAC? A: HK Peptides supplies CJC-1295 with DAC at ≥99% purity by HPLC with full COA documentation.
Q: How should CJC-1295 with DAC be stored for research use? A: Lyophilized CJC-1295 with DAC should be stored at -20°C. Reconstituted solutions at 4°C for short-term use (up to 7 days).